Werth Ventures

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.